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Over the past 30 years, reported cases of
animal rabies in the United States have
increased, from fewer than 5,000 per year in
the early 1960s to almost 10,000 per year in
the mid-1990s (1,2). Most of the increase is
attributable to the spread of raccoon rabies
from Florida to the northeastern states (1).
The impact of this epizootic has been
considerable. For example, hospitals in
Connecticut reported a 2,000% increase in
the annual number of postexposure rabies
prophylaxis treatments after raccoon rabies
was first detected in the state in 1991 (3).
Postexposure prophylaxis costs $2,000 to
$3,000, or more, per person (3,4). In addition,
a raccoon rabies epizootic increases other
costs, including those associated with animal
control and laboratory diagnosis (5; Tysmans,
J., Costs of rabies in Cumberland County,
NC: 1993 and 7/1/94-6/30/95 [MPH thesis],
Chapel Hill (NC): Dept. of Health Policy and
Admin., Univ. of North Carolina, Chapel
Hill, 1996).
Oral vaccines offer a potential solution to
rabies in wildlife populations (6,7). The
spread of rabies in foxes in an area of
Switzerland was halted when an oral vaccine
was used to vaccinate 60% of the fox
population (8). An oral vaccine to control
raccoon rabies (9) is undergoing evaluation
in New York and Massachusetts (10,11).
Also, large-scale programs are using an oral
vaccine against rabies in coyote and gray fox
populations in Texas (12).
Uhaa et al. (5) examined the economics of
using an oral vaccine in Hunterdon and
Warren Counties, New Jersey. However,
their study was limited to a 5-year period
and only to costs borne by the two counties.
To aid the collection of data needed to
conduct a cost-benefit analysis of the use of
an oral vaccine in large areas (e.g., an entire
state) and over prolonged periods (e.g., 30
years), this article outlines some basic
premises required for such an analysis and a
generic cost-benefit model, which can be
modified to fit specific geographic areas.
Since many of the necessary data for the
model are still being collected, the data used
in the model are illustrative rather than
definitive.
Any evaluation of the costs and benefits
of using an oral vaccine to protect wild
raccoon populations must be based on three
premises: 1) Oral vaccine is distributed on a
per unit area basis, calculated by using
estimates of raccoon population density (i.e.,
a predetermined number of baits per raccoon
times the number of raccoons per unit area).
Costs of an oral vaccine  program, therefore,
are expressed in $/unit area. 2) To compare
costs and benefits, all benefits that might
accrue because of oral vaccine use must also
be converted into $/unit area. 3) The cost
savings (benefits) must be adjusted to match
three broad, time-based categories describ-
ing different stages of an epizootic: pre-
epizootic, epizootic, and post-epizootic (ra-
bies still present in the population). The
greatest cost savings is likely to occur during
the epizootic since this stage is typically
associated with the highest cost of raccoon
rabies control (5; Tysmans, J., MPH thesis,
1996). In New Hampshire, for example, the
annual number of requests for Animal
Damage Control services involving raccoons
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went from 250 per year in pre-epizootic years
(1988-1991), to 667 during an epizootic year
(1993), and then declined to 165 in the post-
epizootic years (13).
The Model
 A cost-benefit model with a societal
perspective was constructed (on Excel 5.0,
Microsoft, Inc.) by using a discount rate of
3% (14) over 30 years to provide a Net
Present Value (NPV).
1 The costs of a raccoon
rabies vaccination program include purchas-
ing and distributing the oral vaccine in bait
form. The benefits of such a program are the
direct and indirect cost savings obtained by
successfully halting or preventing a raccoon
rabies epizootic and subsequent enzooticity.
Since the vaccine technology is new, and no
data exist on how the technology might
change over the 30 years, it is assumed that
the real costs and benefits are constant over
the 30 years. Parameters and values used in
the model are presented in Table 1.
Two Distribution Scenarios
Since what constitutes an “ideal” plan for
large-scale oral vaccine bait distribution is
not known, two scenarios were constructed.
The area covered and the rate of barrier
movement were chosen merely for illustra-
tion. Once actual proposals are made, the
area covered and the time line may be
modified to suit specific geographic areas.
The first scenario assumes that bait is
distributed in ever-expanding circles, start-
ing with an area covered by a radius of 20 mi
(area: 1,257 sq. mi). This area would be
baited for 2 years. In the third year, the
radius of the circle would be increased to 25
mi. The area between the 20-mi and 25-mi
radius would then be baited for 2 years, at
which time the radius defining the outer
boundary would be increased by another 5
mi. This process would continue for 20 years,
at the end of which the radius of the circle
would be 65 mi, encompassing 13,273 sq. mi,
which is approximately equal to one-third
Table 1: Illustrative data used to examine the costs and benefits of
controlling raccoon rabies with an oral vaccine
Item Baseline Values used for
case sensitivity analyses
Discount rate 3% 0%, 5%
Timeline 30 years     -
Oral vaccine density 250 units/sq. mi 100-300 units/sq. mi
Raccoon density 50/sq. mi threshold analysis
Baits required/raccoon 5 threshold analysis
Cost of oral vaccine bait $1.50/unit threshold analysis
Cost of distribution $100/sq. mi $260a
Benefits: Cost savings
During epizootic yearsb $1.52/person/yr $2.61/person/yearb
During post-epizootic $0.30/person/yr    -
yearsb
Density human population 103/sq. mi    -
Distribution costs:cost savings
 Ratio of max. $/sq. mi 1:1.57 1:1.03
Sensitivity analysis
Cost of pet vaccination    - $16/pet
Extra vaccinations:    - 11/sq. mi
epizootic
Extra vaccinations:    - 2.75/sq. mi
post-epizootic
aSource: New Jersey data (1).
bOn the basis of the New Jersey data (1), four categories of costs contribute
to the cost-savings: animal control, laboratory diagnoses, educational
activities, and human pre- and post-exposure treatments.
the area of New York State.
At the end of the 20 years, a
10-year period would follow
during which a 5-mi wide
barrier zone would be baited
every year. The yearly and
cumulative total areas baited
are shown in Figure 1. The
barrier zone is necessary
because the described plan
cannot guarantee elimina-
tion, and the area covered by
a vaccine program is vulner-
able to the reintroduction of
rabid animals. The second
scenario considers the entire
13,273 sq. mi baited during
the first 2 years, followed by
28 years of baiting a 5-mi-
wide barrier zone.
Costs: Bait
In an economic analysis,
opportunity costs should be
used (15). However, the
vaccine is still experimental,
1A cost-benefit analysis uses the following formula (15):
where: t = year, from t= 0, . . ., n; r = discount rate.
Threshold costs were calculated by altering the vaccine cost so that benefits minus costs, when discounted and
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and data concerning discount prices could
not be obtained. Therefore, the cost of oral
vaccine in bait form was calculated at $1.50
per unit. This is the cost reported for trials of
the oral vaccine in New York State (C.
Hanlon, unpublished report, New York State
Department of Health, 1995). In lieu of
accurate opportunity costs, a sensitivity
analysis evaluates the threshold price (i.e.,
NPV = $0) of the vaccine. This threshold
value can then be compared with actual
opportunity costs when more data become
available.
Costs: Bait Density
The bait density required to successfully
halt or stop raccoon rabies has not been
definitively determined (10,11,16,17). Rac-
coon density can vary enormously with local
ecology and weather (16,18-20). On the basis
of densities currently under trial, for each of
the two scenarios it is assumed that bait is
distributed at 250 units per sq. mi, with an
assumed raccoon density of approximately
50 per sq. mi (i.e., five baits per raccoon).
Bait density is also the subject of sensitivity
analysis.
Costs: Distribution
Distribution costs for oral rabies vaccine
have yet to be comprehensively documented.
In current trials in New York and Massachu-
setts, bait was dropped by people walking
and from aircraft, helicopters, and cars,
depending on the terrain and available
resources. The use of some vehicles has been
donated, as have large amounts of personnel
time; therefore, their cost is difficult to
determine (an economic analysis must
contain such costs). To illustrate the generic
model, total distribution costs were assumed
to be $100 per sq. mi. This cost is also the
subject of a sensitivity analysis.
Benefits: Cost-savings
In the model described here, the benefits
from using the oral vaccine are assumed to be
the cost savings derived directly from
preventing a raccoon-related rabies epizootic
and post-epizootic. These cost savings are,
therefore, the difference between the pre-
epizootic costs of controlling rabies and the
costs incurred during the epizootic and post-
epizootic periods. It was assumed that a
rabies epizootic lasts 2 years (1) and that the
years following were defined as post-
epizootic. The direct costs associated with
the control of animal rabies have been listed
(5) and can be broken down into four
categories. These categories, with the
estimated proportional contribution to the
entire cost savings, are animal control costs
(41%); laboratory diagnosis costs (13%);
education and administration costs (9%); and
human costs, such as pre- and post-exposure
prophylaxis treatments (37%). Just as
opportunity costs should be used for input
costs, so potential cost savings should be
valued at costs and not charges (15). For
example, the average operating cost-to-
charge ratio for urban hospitals in New York
is 0.635:1 (15).
To illustrate the generic model, data from
New York (Harris-Valente et al., unpub-
lished report, 1995) were used to provide a
Figure 1. Annual and cumulative total areas
baited with oral vaccine using an expanding circle
scenario
Notes: Initial circle has a radius of 20 mi,
expanded out by 5 mi every 2 years. After 20
years, radius is 65 mi. Thereafter, a 5-mi wide
boundary is maintained around the circle for the
next 10 years.
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preliminary estimate of cost savings ($1.52
per person), which will occur during the
epizootic phase. The same data source
yielded a figure of $0.30 per person during
the post-epizootic phase. These savings per
person are converted to savings per unit area
as follows: On the basis of population
estimates (21) from 53 counties in New York
State, the median population density was
estimated at 103 persons per sq. mi (25th
percentile = 67; 75th = 204). Thus, for the
areas baited, the savings were calculated at
$156.56 per sq. mi for the first 2 epizootic
years ($1.52 per person x 103 persons per sq.
mi), and $30.90 per sq. mi for the post-
epizootic years ($0.30 per person x 103
persons per sq. mi). Cost-savings data from
New Jersey (5) are used in the sensitivity
analysis.
Distribution Costs: Cost-savings Ratio
The relative importance of distribution
costs (excluding costs of vaccine) with
respect to the amount of cost savings can be
examined by constructing a distribution
costs:cost savings ratio on a per-unit-area
basis. Thus, the baseline case of $100 per sq.
mi distribution costs and maximum cost
savings during epizootic years of $156.56 per
sq. mi ($1.52 per person x 103 persons per sq.
mi) gives a ratio of 1:1.57. This ratio can be
altered for sensitivity analyses.
 Sensitivity Analyses: Animal Vaccinations
The proportion of household pets and
domesticated animals vaccinated before an
epizootic can be quite low. For example, in
Cumberland County, North Carolina, it was
estimated that only 20% of dogs and cats
were vaccinated against rabies before the
epizootic (Tysmans, J., MPH thesis, 1996).
During an epizootic, public health officials
often encourage or enforce pet vaccinations,
and vaccination rates often increase (5;
Tysmans, J., MPH thesis, 1996). Successful
elimination of raccoon rabies from an area
could be considered a good reason for
allowing vaccination rates to remain at lower
levels, thus avoiding the costs associated
with increased vaccinations. However debat-
able this proposition is, the economic impact
of considering reduced pet vaccinations as a
benefit is demonstrated by rerunning the two
distribution scenarios and including the
potential cost savings associated with
reduced pet vaccination levels.
An example of the savings estimate
follows: In 1991, there were 52.5 million dogs
and 57 million cats in the United States (22),
an average of 0.41 pets per person. During
pre-epizootic periods, 0.14 pets per person
(32% of average pets per person) are
vaccinated each year against rabies (5). In
the epizootic year this rate increased to 0.24
pets per person (55% of average pets per
person) (5). Thus, during an epizootic period,
there is an increase of approximately 11
extra pet vaccinations per sq. mi (0.24 - 0.14
pets per person x 103 persons per sq. mi). Pet
vaccinations are costed at $16 per pet
(Tysmans, J., MPH thesis, 1996). When
baseline figures are used for distribution
costs and cost savings (Table 1), a total
distribution cost:cost savings ratio of 1:3.33
is calculated. No data are available concern-
ing post-epizootic pet vaccination rates, and
it is arbitrarily assumed that there are 2.75
extra pet vaccinations in post-epizootic
stages (25% of the epizootic increase).
Additional Sensitivity Analyses
The impact of two alternate discount
rates (0% and 5%) was evaluated, and the
impact of higher distribution costs was
assessed. In New Jersey (5), the costs of
distribution were calculated at approxi-
mately $260 per sq. mi, while cost savings
during the epizootic period were calculated
at $2.60 per person (without reduced pet
vaccinations considered as a benefit). This
gives a distribution costs:cost savings ratio
of 1:1.03 (compared with 1:1.57 in the
baseline scenario) increasing the costs of
distribution relative to cost-savings. The
impact of removing the cost of having to
continuously bait a barrier zone around
areas covered by previous vaccination
programs was then considered. In the first
distribution scenario, costs associated with
baiting a barrier for years 21 through 30
were removed from the model. In the second
distribution scenario, it was assumed that
the barrier need only be maintained for 2
years after the first 2 years of baiting (i.e., no
baiting for years 5 through 30). The final
sensitivity analysis used the first distribu-Vol. 2, No. 4—October-December 1996 Emerging Infectious Diseases 347
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tion scenario to examine the threshold price
of oral vaccine for levels of bait density
ranging from 100 sq. mi to 300 sq. mi, and
using three different distribution costs:cost
savings ratios. Threshold price was deter-
mined by altering the price of the vaccine
until the NPV for a given bait density
equaled $0 (see footnote) The first two price
ratios were 1:1.57 (baseline, Table 1) and
1:1.96. The latter represents an arbitrary
increase of +25% in cost-savings relative to
distribution costs. The last price ratio used
for the threshold analyses was constructed
by assuming that reduced rates of pet
vaccination resulted in additional cost-
savings of $176 per sq. mi ($16 per pet x 11
extra vaccinations per sq. mi), giving a ratio
of 1:3.33.
Results: Baseline Case
The first distribution scenario (expand-
ing circles) provides smaller losses than the
second distribution scenario (baiting the
entire area in 2 years, followed by 28 years of
baiting a 5-mi boundary) (Table 2). Consider-
ing the avoidance of increased pet rabies
vaccinations as a benefit improves the NPVs
of both scenarios and changes the NPV of the
expanding circles distribution scenario from
negative to positive. For the baseline case,
using different discount rates changes the
absolute values but not the signs.
Results: Sensitivity Analysis
The smaller distribution costs:cost sav-
ing ratio of 1:1.03 increased the losses
(larger negative NPVs) and reduced the sole
positive NPV to +$0.9 million (3% discount
rate). Eliminating the need for baiting a
protective barrier saves $4.8 million in the
expanding circles scenario ($7.9-$3.1 mil-
lion, 3% discount rate) and $14.8 million in
the entire area scenario ($13.7 million + $1.1
million, 3% discount rate) (Table 2). Figure 2
shows the threshold prices for the oral
Table 2. Net present values (NPV) of different
distribution scenarios for using an oral vaccine
to control raccoon rabies
Baiting scenario NPV without pet NPV with pet
vaccination vaccinationsa
($ millions) ($ millions)
Discount rate Discount rate
0% 3% 5% 0% 3% 5%
Expanding -10.2  -6.2  -4.7   +5.5  +3.1 +2.2
circlesb
Entire area -21.3 -15.7 -13.3   -0.5  -1.1 -1.3
at onceb
Sensitivity analyses
Reduced distribution:savingsc
Expanding            -14.3  -8.5  -6.3   +1.4  +0.9 +0.6
 circles
Entire area           -30.8 -21.9 -18.2  -12.5  -8.9 -7.3
 done at once
No baiting of boundary
Expanding             -0.7  -1.8  -2.1  +14.1  +7.9 +4.5
 circles
Entire area            +2.9  -0.9  -2.3  +23.7 +13.7 +9.7
 at once
aCost savings (benefits) of 11 pets/sq. mi during an
epizootic period, and 2.75 pets/sq. mi during the post-
epizootic period, both at $16/pet.
bExpanding circles assumes start with 20-mi radius,
expanding by 5 mi every 2 years for 20 years, and then
baiting a 5-mi wide boundary for next 10 years. Entire
area assumes baiting 65-mi radius for 2 years,
followed by 28 years of baiting 5-mi wide radius.
cRatio of distribution costs:cost savings is 1:1.03,
based on New Jersey data (1). In baseline scenario,
ratio is 1:1.57.
Figure 2. Threshold prices for the oral vaccine at
different levels of bait density and three
distribution costs:cost-savings ratios for the
expanding circles scenario
Notes: Threshold price occurs at the point that the
net present value of a vaccination program = $0.
The distribution costs:cost-savings ratios are
calculated on a per unit area basis, using the
maximum cost-savings figures (i.e., savings
resulting from avoiding an epizootic).
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vaccine in the expanding circles scenario,
given different levels of bait density used
and three different distribution costs:cost-
savings ratios. At the baseline distribution
costs:cost-savings ratio of 1:1.57, and at bait
density of 250 baits per sq. mi, the threshold
price for the oral vaccine is $0.63 per unit.
When the distribution costs:cost-savings
ratio is increased to 1:1.96, the threshold
price for 250 baits per sq. mi is $0.91 per unit
(+44% from baseline threshold). When
reduced pet vaccinations are considered a
benefit and the distribution costs:cost-
savings ratio increases to 1:3.33, the
threshold prices are always greater than the
$1.50  cost of the vaccine (Figure 2).
Many of the data used in the generic
model are assumed for illustrative purposes.
The results presented here, therefore, should
not be used to decide if a large-scale oral
vaccine program is economically worthwhile.
These results identify at least two priorities:
the need to continue research that will
determine the optimal level of bait density
and the importance of better defining the
distribution costs:cost-savings ratio. Both of
these priorities are the focus of research
efforts in New York and Massachusetts.
The results of the generic model (Table 2)
clearly identify the importance of pet
vaccinations when considering the costs and
benefits of a raccoon vaccination program. It
can be argued that avoidance of increased
pet vaccinations is a benefit only if the laws
requiring small animal vaccinations were
passed solely as a result of the raccoon
epizootic. It could be counterargued that,
because past rabies control programs were so
successful, the current laws are unnecessary
and an economic burden to society. However,
this would suggest that public health
officials would accept a repeal of mandatory
vaccination requirements except under ex-
tenuating circumstances (e.g., a rabies
epizootic). Further, there are other sources
of rabies exposure (e.g., bats), and the risk
for pet exposure from these will most likely
not be altered by a raccoon rabies vaccina-
tion program.
In evaluating an actual proposed rabies
vaccine program, the use of expanding
circles, although more economical than
baiting entire areas at once (Table 2), may be
unrealistic because of natural terrain or
political boundaries. The sensitivity analy-
ses demonstrated the costs of having to
maintain a barrier (Table 2). The only way to
avoid having to maintain a barrier over a
long time may be to conduct a large-scale
program, involving many contiguous states.
However, such a program would pose a
financial burden on governments and, at its
conclusion, would still not stop rabies from
being reintroduced in a manner similar to
that which caused the current epizootic.
In addition to the issues related to
distribution, two important implicit assump-
tions in the model affect costs: 1) the vaccine
is 100% effective in stopping rabies in baited
areas in 2 years; and, 2) rabies is not
reintroduced. Removal of these assumptions
would effectively increase the cost of the
program by requiring increased bait densi-
ties, longer baiting periods, or both. Any of
these situations would move the optimal bait
density in Figure 2 (X-axis) to the right,
further reducing the threshold value of the
vaccine. Obviously, increased costs would
merely increase the negative value of the
NPVs presented in Table 2. The threshold
analysis used here (Figure 2) provides a
basis, even when some data are uncertain,
for discussing discount pricing of the vaccine
with the manufacturers when bulk pur-
chases for large-scale programs are being
planned.
Martin I. Meltzer
Centers for Disease Control and Prevention,
Atlanta, Georgia, USA
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